Kura Oncology, Inc. (KURA)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Kura Oncology, Inc. reported revenue of $67.48M, up 25.2% from the prior year. The company ran a net loss, with a net margin of -412.9%. It held $738.36M in total assets against $564.23M in total liabilities.
Key ratios (FY2025)
-449.9%
Operating margin
-412.9%
Net margin
-160.0%
Return on equity
+25.2%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.48M | $53.88M | $0 | — | — | — | — | — | — | — |
| Operating Income | -$303.63M | -$193.19M | -$165.80M | -$139.87M | — | — | — | — | — | — |
| Net Income | -$278.67M | -$173.98M | -$152.63M | -$135.84M | -$130.47M | -$89.62M | -$63.14M | -$60.45M | -$35.43M | -$27.56M |
| EPS (Diluted) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 | $-1.69 | — | — | — | — |
| Total Assets | $738.36M | $760.16M | $448.94M | $456.31M | $534.05M | $647.21M | $241.97M | $182.38M | $95.85M | $69.82M |
| Total Liabilities | $564.23M | $346.52M | $51.66M | $36.03M | $27.44M | $36.31M | $23.19M | $21.39M | $15.99M | $12.95M |
| Shareholders' Equity | $174.13M | $413.64M | $397.27M | $420.28M | $506.61M | $610.90M | $218.78M | $160.99M | $79.86M | $56.88M |
| Cash & Equivalents | $149.10M | $224.46M | $37.32M | $51.80M | $90.67M | $325.49M | $26.14M | $16.12M | $11.43M | $9.72M |
| Operating Cash Flow | -$64.06M | $134.32M | -$124.82M | -$110.06M | -$104.55M | -$69.83M | -$54.76M | -$48.66M | -$28.44M | — |
| Capital Expenditures | $6.64M | $472.0K | $168.0K | $626.0K | $1.15M | $2.17M | — | — | — | — |
| Shares Outstanding | 87.86M | 78.23M | 74.35M | 68.31M | 66.57M | 66.19M | 45.38M | 38.15M | 29.42M | 19.35M |